Search for a trial

TElmisartan in the management of abDominal aortic aneurYsm
(TEDY)

The aim of this study is to investigate if telmisartan reduces AAA growth

A randomized, double-blind, placebo controlled multiple dose study of subcutaneous ACZ885 for the treatment of abdominal aortic aneurysm

To assess the effect of ACZ885 on AAA size and growth rate as measured with ultrasound at 12 months.Secondary Objectives * To assess the safety and tolerability of monthly 150 mg subcutaneousdoses of ACZ885 in subjects with AAA over a treatment…

Doxycycline for Stabilization of Abdominal Aortic Aneurysms

To test whether 100 mg doxycycline inhibits aneurysm growth

Comparison of a single dose fibrinogen with placebo and the number of blood transfusions after ascending aorta surgery (FIBTEG study)

The purpose of this study is to answer the following question: Leads a primary coagulation corrected with a single dose of fibrinogen concentrate after ascending aorta-arc reconstruction to a decrease in the number of allogenic blood transfusions,…

Deferoxamine in Aneurysmal Subarachnoid Hemorrhage trial

This study has been transitioned to CTIS with ID 2024-514615-10-01 check the CTIS register for the current data. This study investigates the effectivity and the safety of deferoxamine use in patients with aneurysma subarachnoidhemorrhage.

A single-center, randomized, double-blind, two-period cross-over study to investigate the effect of rifampicin on the pharmacokinetics of clazosentan in healthy male subjects.

The purpose of the study is to determine how a single administration of rifampicin influences the uptake and breakdown of clazosentan. Furthermore, the safety and tolerability of clazosentan when administered after administration of rifampicin, will…

Deferoxamine in Aneurysmal Subarachnoid Hemorrhage trial

This study investigates the safety and tolerability of deferoxamine use in patients with aneurysma subarachnoid hemorrhage.

Randomized, double-blind (for clazosentan), placebo- and moxifloxacin-controlled, 3-way cross-over Phase 1 study to assess the effect of two intravenous doses of clazosentan on the QTc interval duration in healthy subjects

This study aims at investigating potential relevant QT effects of clazosentan at supra therapeutic doses in healthy male and female subjects using a concentration/response analysis approach in compliance with the ICH E14 guidance [FDA 2017].Primary…